16 Aug 2021 07:00
SourceBio International plc
("SourceBio", the "Company" or the "Group")
Notice of Half Year Results
Analyst briefing and Investor Presentation
SourceBio International plc (AIM: SBI), the international provider of integrated state-of-the-art laboratory services and products, announces that its Unaudited Half Year Results for the six months ended 30 June 2021 will be announced on Tuesday, 28 September 2021.
Analyst Briefing
A briefing open to analysts will take place remotely via video conference call on Tuesday 28 September at 09:30 (BST). If you would like the log-in details of this call, please contact Walbrook PR at sourcebio@walbrookpr.com.
Investor Presentation
Executive Chairman, Jay LeCoque, and Chief Financial Officer, Tony Ratcliffe, will also provide a live presentation relating to SourceBio International plc Half Year Results Investor Presentation via the Investor Meet Company platform on 28th September 2021 at 16:30 (BST).
The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 09:00 (BST) the day before the meeting or at any time during the live presentation.
Investors can sign up to Investor Meet Company for free and add to meet SourceBio International plc via:
https://www.investormeetcompany.com/sourcebio-international-plc/register-investor
Investors who already follow SourceBio International plc on the Investor Meet Company platform will automatically be invited.
Contacts:
SourceBio International plc | www.sourcebiointernational.com | |
Jay LeCoque, Executive Chairman | Via Walbrook PR | |
Tony Ratcliffe, Chief Financial Officer | ||
Liberum (Nominated Adviser and Broker) | Tel: 020 3100 2000 | |
Bidhi Bhoma / Richard Lindley / Euan Brown | ||
Walbrook PR Limited | Tel: 020 7933 8780 or sourcebio@walbrookpr.com | |
Paul McManus / Sam Allen | Mob: 07980 541 893 / 07502 558 258 | |
About SourceBio International plc www.sourcebiointernational.com
SourceBio is a leading international provider of integrated state-of-the-art laboratory services and products with clients in the healthcare, clinical, life science research and biopharma industries, with a focus on improving patient diagnosis, management and care. Group revenues are derived from four core businesses areas:
• Infectious Disease Testing - a range of COVID-19 testing services for commercial enterprises, private healthcare groups, NHS and the DHSC. Utilising multiple technologies, SourceBio offers screening, gold standard RT-PCR and whole genome sequencing COVID-19 testing solutions and operates under ISO 15189 accreditation required by the DHSC. SourceBio also provides employee testing solutions to industry, direct to consumer home test kits (including 'Fit to Fly', 'Test to Release' and '2 & 8 Day International Travel' approved tests).
• Healthcare Diagnostics - histopathology cancer screening and clinical diagnostic services for the NHS and private healthcare across the UK and Ireland.
• Genomics - DNA sequencing services for pharmaceutical and biotechnology companies, academia, contract research organisations (CROs) and other research groups in the UK, Europe and North America.
• Stability Storage - shelf-life testing services and equipment for pharmaceutical and biotechnology companies, contract manufacturers and analytical testing companies from around the world but primarily in the UK, Ireland and the USA.
More details on Group operations can be found here: www.sourcebioscience.com.
SourceBio International plc (SBI) is listed on the AIM market of the London Stock Exchange.